A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdominal Surgery
Condition(s) studied
Investigational drug(s) / intervention(s)
HSK55718 dose level1: Patients administrated with HSK55718 at dose level 1
HSK55718 dose level2: Patients administrated with HSK55718 at dose level 2
HSK55718 dose level 3: Patients administrated with HSK55718 at dose level 3
Placebo control: Patients administrated with placebo
morphine: Patients administrated with morphine
Study summary
This is a multi-center, randomized, double-blind, double-dummy, placebo/active-controlled study. 200 subjects undergoing abdominal surgery under general anesthesia are planned to be enrolled and randomized into the HSK55718 group, morphine group, and placebo group.
Eligibility
Primary outcome measure(s)
- Sum of Pain Intensity Differences (SPID) — 24 hours
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| The Third Xiangya Hospital of Central South University | Changsha | Hunan | Recruiting |
| Sichuan Provincial People's Hospital | Chengdu | Sichuan | Recruiting |
More Haisco Pharmaceutical Group Co., Ltd. trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07533786 on ClinicalTrials.gov ↗ ← All trials in China